Mike Gaffney

Olympia, WA

Multiple myeloma patient

My name is Mike Gaffney. I am a retired forester from Olympia, Washington, and I have spent much of life enjoying my time outdoors. But in late February of 2011, my life was turned upside down. After suffering from numbness in my feet, I was diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This disease is often described a slower onset but chronic form of Guillain–Barré Syndrome (GBS), where one’s nerves are attacked by one’s own body. It starts with the extremities and works toward the body core. You slowly lose control and function, and you often deal with neuropathic pain which is difficult to relieve. In GBS, the patient often ends up hospitalized and on a ventilator before treatments can begin to do their work.

For 18 months they treated me for CIDP. They began with a loading phase, requiring five consecutive days of six hour infusions of a specialized blood plasma. Following that phase, I received additional infusions for six hours every three to four weeks. The loading phase totaled a whopping $85,000 as an outpatient. On top of that, each follow-up dose was another $10,000. In the end, it was a total of over $175,000. This lasted 18 months until my lack of response to the infusions and a closer study of my broad range of symptoms led my doctors to suspect I actually had POEMS Syndrome, a rare variant of Multiple Myeloma — a disease with its own expensive medications. Had I not had excellent private insurance during my treatment for CIDP, the costs would have had a devastating effect to my family’s finances that likely would have resulted in a decline in my health.

Share your story

The prescription drug pricing system in the U.S. is rigged against patients. We are fighting to change that.

Patients For Affordable Drugs will collect patient stories and amplify the voices of patients to make policymakers understand the heavy toll of high priced drugs.

Share your story


Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.